Avidity Biosciences to Participate in Upcoming Investor Conference
Provided By PR Newswire
Last update: Oct 16, 2025
SAN DIEGO, Oct. 16, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a panel discussion at the following investor conference:
Read more at prnewswire.com
